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Background/aim: Young-onset hypertension is a form of condition diagnosed in patients aged below 40. Cytokines such as interleukin
(IL)-6 and also MCP-1 may play a role in the development of arterial hypertension. Aortic stiffness can be detected by measuring pulse
wave velocity (PWV). We aimed to explore the relationship between inflammation and aortic stiffness and investigate their roles in the
etiology of young-onset hypertension.
Materials and methods: We enrolled 16 patients diagnosed with young-onset hypertension and 16 volunteers without hypertension.
The plasma levels of MCP-1 and IL-6 were determined using an enzyme-linked immunosorbent assay and quantitative enzyme-linked
immunoassay, respectively. Carotid-femoral PWV was measured using an arteriograph device.
Results: Compared with those in normotensive controls, the plasma levels of IL-6 and MCP-1 and the PWV values were significantly
higher in patients with young-onset hypertension (P < 0.001). PWV values were also positively correlated with the levels of MCP-1 and
IL-6. However, no statistically significant difference was noted in intima-media thickness between

the two groups (P = 0.224).
Conclusion: In this study, increased PWVs and the levels of inflammation markers were associated with aortic stiffness and inflammation
in patients with young-onset hypertension, suggesting they have a role in the etiology of hypertension.
Keywords: Aortic stiffness, young-onset hypertension, inflammation markers

1. Introduction
Hypertension is a major cause of mortality worldwide
[1]. Young-onset hypertension is a form of this condition
diagnosed in patients aged below 40. In an epidemiological
study, the incidence of young-onset hypertension was
approximately 0.1%, and sex, genetics, and obesity were
the risk factors [2]. The predominant form of hypertension
in individuals aged below 50 is essential hypertension,
while isolated systolic hypertension is more commonly
seen among elderly individuals [3,4].
Experimental evidence suggests that hypertension
functions to aggravate inflammation by promoting the
expression of cytokines [5,6]. A study conducted on healthy
men demonstrated a correlation between increased blood
pressure (hypertension) and elevated levels of circulating
interleukin (IL)-6 [7]. Increase in IL-6 was also reported
in response to the infusion of angiotensin II in humans,
demonstrating a direct relationship between the two [8,9].
In addition to IL-6, MCP-1, a key chemokine involved
in the onset of inflammation, may play a role not only
in various pathophysiological processes occurring in

the cardiovascular system but also in the development
of arterial hypertension [10,11]. Vascular endothelial
cells stimulate the expression of MCP-1 by mediating
the inflammatory cytokines IL-1, IL-4, IL-6, and tumor
necrosis factor-α [12].
Aortic stiffness contributes to vascular diseases by
inducing vascular strain and endothelial dysfunction.
Moreover, pulse wave velocity (PWV) has been widely
accepted for diagnosing aortic stiffness in clinical practices
[13–15]. Carotid-femoral PWV is recommended by the
European Society of Hypertension, the European Society
of Cardiology, and the American Heart Association as a
clinical marker for the classification of cardiovascular risk
in patients with hypertension [16–18]. The carotid intimamedia thickness (IMT) is also widely used for detecting
early atherosclerosis and is associated with increased
cardiovascular risk factors, such as hypertension, diabetes
mellitus, hypercholesterolemia, obesity, and coronary
artery disease [19–22].
However, to date, the etiology of young-onset
hypertension has been unclear. In this study, we aimed
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to explore the relationship between inflammation and
aortic stiffness and investigate their roles in the etiology of
young-onset hypertension.
2. Materials and methods
2.1. Patients
Between December 2017 and May 2018, 16 patients
diagnosed with young-onset hypertension (patient group)
and 16 volunteers (control group) without hypertension
(all aged below 40) were included in the study. Their
sedimentation rates, C-reactive protein levels, and white
blood cell levels were within normal limits. Patients with
rheumatic disease, hyperlipidemia, and acute or chronic
infections were excluded. Both groups were matched
for age and sex. Informed consent was obtained from all
participants, and the study was approved by the ethics
committee of the Faculty of Medicine of Afyonkarahisar
University of Health Sciences.
2.2. Enzyme-linked immunosorbent assay (ELISA)
The plasma levels of MCP-1 were determined using an
ELISA kit (BMS281TEN; eBioscience, Vienna, Austria) as
per the manufacturer’s recommendations. Absorbance was
measured at 450 nm using a spectrophotometer (BioTek,
Epoch Microplate Spectrophotometer, Winooski, VT,
USA). The limit of detection and coefficient of interassay
variation were 2.31 pg/mL and 8.7%, respectively. The level
of IL-6 was measured using a quantitative enzyme-linked
immunoassay kit (Elabscience, Houston, TX, USA).
2.3. Determination of carotid-femoral PWV
Carotid-femoral PWV was measured using an arteriograph
device (TensioMed, Budapest, Hungary). The pulse
waveforms of the common carotid and femoral arteries
were sequentially acquired. Subsequently, for determining
PWV, the distance from the suprasternal notch to the
femoral artery was divided by the time interval between
the waves.
2.4. IMT measurements
The IMT of the right and left common carotid arteries was
measured from the distant walls based on the Mannheim
carotid IMT consensus [23]. An Aplio MX duplex Doppler
ultrasonography device (Toshiba, Otawara, Tochigi,
Japan) and a 7.5-MHz probe were used to obtain images
of the intima media of the carotid artery. The best image
was acquired when the patient was in the supine position.
After obtaining the mean and maximum IMTs of the distal
walls of the right and left arteries at 1–2 cm proximally
to the bulb, the average of the mean values of
 the two
measurements was calculated.
2.5. Statistical analysis
All data were analyzed using SPSS 21.0 (IBM Corp.,
Armonk, NY, USA). Comparison of the categorical and
continuous variables was performed using the chi-square

and Mann–Whitney U tests, respectively. The association
between MCP-1, IL-6, and PWV was investigated with
Spearman’s correlation coefficient. An a priori power
analysis could not be conducted owing to the unavailability
of pilot data. Therefore, a post hoc power analysis was
conducted to confirm that the current study had adequate
power (99%).
3. Results
Participant demographics are shown in Table 1. Among 16
patients with young-onset hypertension who participated
in the study, nine were males and seven were females, with
a mean age of 31.6 (range: 18–40) years. The control group
comprised 16 individuals, eight males and eight females,
with a mean age of 29.9 (range: 18–39) years. The body
mass index (BMI) and the mean levels of low-density
lipoprotein (LDL) and triglycerides of the two groups are
shown in Table 1. There were no significant differences in
any of the variables examined between the patient and the
control groups.
The mean level of IL-6 significantly differed between
the patient (152.45 ± 80.93; range: 52.96–317.08 pg/mL)
and the control groups (5.73 ± 5.94; range: 1.02–25.53 pg/
mL; P < 0.001). The level of MCP-1 was significantly higher
in the patient group (293.15 ± 148.76; range: 34.55–614.63
pg/mL) than that in the control group (13.49 ± 41.38;
range: 0.39 ± 168.42 pg/mL; P < 0.001).
Mean PWV in the patient group (11.22 ± 2.54; range:
7.5–16 m/s) was significantly higher than that of the
control group (7.36 ± 1.86; range: 4.6–10.2 m/s; P < 0.001).
PWV was positively correlated with the levels of MCP-1
and IL-6. PWV level was positively correlated with IL-6 (r
= 0.656, P <0.001) and MCP-1 (r = 0.614, P <0.001).
Mean IMT in the patient group (0.57 ± 0.14; range:
0.3–0.9 mm) was not significantly different from that in
the control group (0.5 ± 0.1; range: 0.3–0.7 mm; P = 0.224)
(Table 2).
4. Discussion
To the best of our knowledge, this is the first study to
demonstrate that patients with young-onset hypertension
have significantly higher levels of plasma MCP-1 and IL-6
and aortic stiffness than normotensive individuals. These
results support the use of IL-6 and MCP-1 as the biological
markers of vascular impairment.
The earlier the onset of hypertension is, the longer
the exposure time to the disease and the higher the risk
of cardiovascular events will be. Therefore, appropriately
identifying and treating the underlying pathogenesis
of young-onset hypertension is important to prevent
cardiovascular events. However, the literature on this
subject is not sufficient. A study involving young adults
demonstrated that the main hemodynamic abnormality

1749

GÖKASLAN et al. / Turk J Med Sci
Table 1. The demographic features of patients with young-onset hypertension and
normotensive controls.
Patients (n = 16)
(mean ± SD)

Controls (n = 16)
(mean ± SD)

P-value

Age (mean)

31.6 ± 8.5

29.9 ± 5.9

0.642

Sex (male)

9 (56%)

8 (50%)

0.469

BMI (kg/m2)

27.49 ± 3.51

24.61 ± 4.36

0.094

LDL (mg/dL)

95.8 ± 18.4

97.2 ± 20.6

0.128

Triglyceride (mg/dL)

183.2 ± 25.6

178.5 ± 23.2

0.076

Table 2. Mean levels of IL-6, MCP-1, PWV, and IMT of patients with youngonset hypertension and normotensive controls.
Patients
(mean ± SD)

Controls
(mean ± SD)

P-value

IL-6 (pg/mL)

152.45 ± 80.93

5.73 ± 5.94

<0.001

MCP-1(pg/mL)

293.15 ± 148.76

13.49 ± 41.38

<0.001

PWV (m/s)

11.22 ± 2.54

7.36 ± 1.86

<0.001

IMT (mm)

0.57 ± 0.14

0.5 ± 0.1

0.224

underlying essential hypertension may be increased
peripheral vascular resistance, which causes vascular
remodeling in the arteries, involving extracellular matrix
deposition and inflammation [24].
Previous studies showed that vascular inflammation
caused vascular damage and played a key role in the
pathogenesis and progression of hypertension [25–27].
However, the role of inflammatory cytokines in the
mechanism and progression of hypertension remains
unclear. The stimulation of human vascular smooth
muscle cells by angiotensin II, the main regulator of blood
pressure, resulted in increased expression and release of
IL-6 [28–30]. IL-6 increased vascular smooth muscle cell
proliferation, which is a characteristic of the early stages of
hypertension [31]. Additionally, MCP-1 also contributed
to the onset of inflammation by promoting the uptake of
inflammatory cells into the vessel wall [32]. Furthermore,
increased blood vessel tension due to high blood pressure
increased the expression of MCP-1 mRNA in human
vascular endothelial cells, which further potentiated
the secretion of MCP-1 [33,34]. Thus, in young-onset
hypertension, elevated levels of MCP-1 and IL-6 in the
vascular endothelium may indicate the stimulation of
cellular immunological processes that contribute to early
vascular aging and the development of hypertension
[35,36].
The present study provides evidence regarding
high levels of IL-6 and MCP-1 and a predisposition to
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inflammation in patients with young-onset hypertension
compared with those in normotensive individuals. These
mechanisms may partly explain the relationship observed
between increased levels of blood pressure, MCP-1, and
IL-6, suggesting that IL-6 and MCP-1 may serve as the
biological markers of vascular impairment.
Another
known
independent
predictor
of
cardiovascular disease is increased aortic stiffness,
which is considered to be an important cardiovascular
risk factor [37,38]. Although increased aortic stiffness
can be determined by measuring pulse waves, the latter
is an independent predictor of poor cardiovascular
outcomes in patients with essential hypertension [24,39].
A metaanalysis found that a 1-m/s increase in PWV was
associated with an 11% increase in cardiovascular deaths
[37].
Carotid-femoral and brachial-ankle PWVs are the
two most commonly used PWV measurements. Brachialankle PWV calculation involves both elastic and muscular
arteries, and is considered to be a predictor of aortic
stiffness. Conversely, carotid-femoral PWV, which only
involves measurement of the elastic artery, is accepted
as a better indicator [17]. Aortic PWV increases with
age and accelerates with the presence and severity of
hypertension [40,41]. In a study using carotid-femoral
PWVs, hypertension was associated with the progression
of aortic stiffness in young patients compared with
those in normotensive subjects [42]. The findings of this
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study are in concordance with those in the literature.
Carotid-femoral PWV increased in patients with youngonset hypertension compared with those in the control
group. This suggests that in addition to predisposition
to inflammation, increased aortic stiffness contributes to
the etiology of young-onset hypertension. Furthermore,
the positive relationship between PWVs and the levels of
MCP-1 and IL-6 indicates that aortic stiffness may play a
role in the etiology of young-onset hypertension.
Most young individuals with hypertension show
early vascular changes despite short-term exposure to
the disease [43]. As increased carotid IMT is strongly
associated with the early stages of vascular atherosclerosis
in young adults, this measure can be used to evaluate early
atherosclerosis and predict cardiovascular events [43].
However, in this study, we found no significant increase
in carotid IMT or the evidence of early atherosclerosis.
Reportedly, an increase in carotid IMT is adaptive to
medial hypertrophy rather than intimal hypertrophy
in young patients with hypertension [43–45]. In our

study, the lack of difference in the carotid IMTs in
 the
patient group compared with the difference observed in
the control group may be attributed to the small media
of the carotid artery and the inability to radiologically
detect medial hypertrophy [46,47]. In addition, the
patients included in this study were young; accordingly,
atherosclerosis is not expected in this age group, which
may be the reason why no significant difference was
observed between the two groups regarding IMT.
However, this was strictly a clinical study, and additional
histopathological studies are warranted to confirm the
findings. The other limitation of this study was that
the patient group was not compared with hypertensive
patients over 40 years of age. Such a comparison could
increase the effectiveness of the study.
In conclusion, increased PWV and the levels of
inflammatory markers were associated with aortic
stiffness and inflammation in patients with young-onset
hypertension, suggesting that these factors have a role in
the etiology of hypertension.
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